BMS

Key TakeawaysChristopher Boerner, CEO of Bristol Myers Squibb, will participate in a fireside chat at the Citi Global Healthcare Conference. The event is...

Key TakeawaysViz.ai's Viz HCM™ recognized as the Best Digital Health Solution in 2024. The AI-powered tool accelerates the diagnosis of Hypertrophic Cardiomyopathy (HCM). ...

Key TakeawaysImplement value-based reimbursement models to incentivize innovation and improve patient access. Streamline health technology assessments across EU member states to reduce approval...

Key TakeawaysBristol Myers Squibb (BMS) presented over 90 data disclosures at ASH 2024, including breakthroughs in hematology and cell therapy. The presentations underline...

Key TakeawaysOpdivo-Yervoy combination offers a novel first-line treatment option for MSI-H/dMMR metastatic colorectal cancer. Enhanced survival rates could set a new standard in...

Key TakeawaysRepotrectinib shows strong efficacy in treating advanced ROS1-positive NSCLC and NTRK-positive solid tumors. Positive CHMP recommendation paves the way for EU approval...

Key TakeawaysPositive CHMP opinion for Opdivo® and Yervoy® as first-line treatment for metastatic colorectal cancer. The CheckMate -8HW trial showed a 79% reduction...

Key TakeawaysBristol Myers Squibb (BMS) will showcase new clinical and health economics outcomes research (HEOR) data on COBENFY™ for schizophrenia at Psych Congress...

Key TakeawaysDecision made to discontinue enrollment in the KarMMa-9 trial due to changing treatment landscape and enrollment challenges. Trial aimed to evaluate Abecma®...

Key TakeawaysThe U.S. FDA held an ODAC meeting to assess PD-L1 expression cutoffs for immune checkpoint inhibitors in gastric and esophageal cancers. The...

Key TakeawaysMultiple myeloma treatment advancements have led to a reduced number of eligible patients for the KarMMa-9 trial, prompting the discontinuation of enrollment. ...

Key TakeawaysIn the Phase 3b/4 PSORIATYK SCALP trial, Sotyktu demonstrated a significant improvement in moderate-to-severe scalp psoriasis, with 48.5% of patients achieving clear...

Key TakeawaysThe U.S. FDA has approved Opdivo in combination with chemotherapy for the perioperative treatment of resectable non-small cell lung cancer, marking a...

Key TakeawaysClinical trials indicate significant symptom reduction in schizophrenia patients. Cobenfy offers an innovative treatment option by targeting cholinergic receptors. Patients must be...

Key TakeawaysThe FDA has approved Bristol Myers Squibb's COBENFY™, marking the first new pharmacological approach for treating schizophrenia in decades by targeting M1...